Comparison of results of Fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program

被引:8
|
作者
Pfaller, MA
Hazen, KC
Messer, SA
Boyken, L
Tendolkar, S
Hollis, RJ
Diekema, DJ
机构
[1] Univ Iowa, Coll Med, Div Med Microbiol, Dept Pathol, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Med, Iowa City, IA 52242 USA
[4] Univ Iowa, Roy J & Lucille a Carver Coll Med, Iowa City, IA 52242 USA
[5] Univ Iowa, Coll Publ Hlth, Iowa City, IA 52242 USA
[6] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA
关键词
D O I
10.1128/jcm.42.8.3607-3612.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The accuracy of antifungal susceptibility tests is important for accurate resistance surveillance and for the clinical management of patients with serious infections. Our main objective was to compare the results of fluconazole disk diffusion testing of Candida spp. performed by ARTEMIS participating centers with disk diffusion and MIC results obtained by the central reference laboratory. A total of 2,949 isolates of Candida spp. were tested by NCCLS disk diffusion and reference broth microdilution methods in the central reference laboratory. These results were compared to the results of disk diffusion testing performed in the 54 participating centers. All tests were performed and interpreted following NCCLS recommendations. Overall categorical agreement between participant disk diffusion test results and reference laboratory MIC results was 87.4%, with 0.2% very major errors (VME) and 3.3% major errors (ME). The categorical agreement between the disk diffusion test results obtained in the reference laboratory with the MIC test results was similar: 92.8%. Likewise, good agreement was observed between participant disk diffusion test results and reference laboratory disk diffusion test results: 90.4%, 0.4% VME, and 3.4% ME. The disk diffusion test was especially reliable in detecting those isolates of Candida spp. that were characterized as resistant by reference MIC testing. External quality assurance data obtained by surveillance programs such as the ARTEMIS Global Antifungal Surveillance Program ensure the generation of useful surveillance data and result in the continued improvement of antifungal susceptibility testing practices.
引用
收藏
页码:3607 / 3612
页数:6
相关论文
共 38 条
  • [1] Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program
    Pfaller, MA
    Boyken, L
    Messer, SA
    Tendolkar, S
    Hollis, RJ
    Diekema, DJ
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (10) : 5208 - 5213
  • [2] Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program
    Pfaller, Michael A.
    Boyken, Linda
    Hollis, Richard J.
    Kroeger, Jennifer
    Messer, Shawn A.
    Tendolkar, Shailesh
    Diekema, Daniel J.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 65 (01) : 27 - 34
  • [3] Results from the ARTEMIS DISK global antifungal surveillance study:: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing
    Pfaller, MA
    Diekema, DJ
    Rinaldi, MG
    Barnes, R
    Hu, B
    Veselov, AV
    Tiraboschi, N
    Nagy, E
    Gibbs, DL
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (12) : 5848 - 5859
  • [4] Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005:: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing
    Pfaller, M. A.
    Diekema, D. J.
    Gibbs, D. L.
    Newell, V. A.
    Meis, J. F.
    Gould, I. M.
    Fu, W.
    Colombo, A. L.
    Rodriguez-Noriega, E.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (06) : 1735 - 1745
  • [5] Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion
    Pfaller, M. A.
    Diekema, D. J.
    Gibbs, D. L.
    Newell, V. A.
    Ellis, D.
    Tullio, V.
    Rodloff, A.
    Fu, W.
    Ling, T. A.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (04) : 1366 - 1377
  • [6] Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program
    Pfaller, Michael A.
    Diekema, Daniel J.
    Gibbs, David L.
    Newell, Vance A.
    Barton, Richard
    Bijie, Hu
    Bille, Jacques
    Chang, Shan-Chwen
    Martins, Maria da Luz
    Duseh, Adriano
    Dzierzanowska, Danuta
    Ellis, David
    Finquelievich, Jorge
    Gould, Ian
    Gur, Deniz
    Hoosen, Anwar
    Lee, Kyungwon
    Mallatova, Nada
    Mallie, Michele
    Peng, N. G. Kee
    Petrikos, George
    Santiago, Axel
    Trupl, Jan
    Abeelev, Ann Marie VanDen
    Wadula, Jeannette
    Zaidi, Mussaret
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2010, 67 (02) : 162 - 171
  • [7] Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing
    Pfaller, M. A.
    Diekema, D. J.
    Gibbs, D. L.
    Newell, V. A.
    Bijie, H.
    Dzierzanowska, D.
    Klimko, N. N.
    Letscher-Bru, V.
    Lisalova, M.
    Muehlethaler, K.
    Rennison, C.
    Zaidi, M.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (01) : 117 - 123
  • [8] Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole:: Geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
    Pfaller, M. A.
    Diekema, D. J.
    Mendez, M.
    Kibbler, C.
    Erzsebet, P.
    Chang, S. -C.
    Gibbs, D. L.
    Newell, V. A.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (10) : 3551 - 3556
  • [9] Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.:: Results from a global Antifungal Surveillance Program
    Pfaller, M. A.
    Messer, S. A.
    Boyken, L.
    Tendolkar, S.
    Hollis, R. J.
    Diekema, D. J.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (02) : 551 - 559
  • [10] Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis:: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005
    Pfaller, M. A.
    Diekema, D. J.
    Gibbs, D. L.
    Newell, V. A.
    Ng, K. P.
    Colombo, A.
    Finquelievich, J.
    Barnes, R.
    Wadula, J.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (03) : 842 - 849